{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:46:17Z","timestamp":1791906377238,"version":"4.3.4"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"\n Importance<\/jats:title>\n The long-term efficacy of amyloid-targeting therapies hinges on their ability to slow downstream neuropathologic change, but little is known about the influence of amyloid clearance on tau pathology and neurodegeneration.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the postmortem and in vivo association between amyloid levels and downstream neuropathology after treatment with aducanumab in a patient with patchy areas showing minimal residual amyloid levels.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This clinicopathologic case report from a single academic memory center includes a male carrier of the p.R47H\n TREM2<\/jats:italic>\n variant, which is associated with a higher risk of Alzheimer disease, who was in his 50s, had mild cognitive impairment, and received aducanumab while participating in a randomized clinical trial. Fourteen untreated controls, who were matched by age or presence of the\n TREM2<\/jats:italic>\n variant, also are included.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n The male carrier of the p.R47H\n TREM2<\/jats:italic>\n variant had received 30 doses of aducanumab (cumulative dose of 280 mg\/kg) over 4.5 years.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Neuropathologic evaluation at autopsy, positron emission tomography to measure standardized uptake value ratio as a measure of amyloid and tau levels, and magnetic resonance imaging to determine longitudinal change in cortical thickness.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Four years after receiving the final dose of aducanumab, the patient died. An autopsy showed variable levels of amyloid pathology, including brain regions with very low levels of amyloid juxtaposed with brain regions that had typically high levels of amyloid in the deep cortical layers and only low levels of amyloid in the superficial cortical layers. Compared with the brain regions of the untreated controls, the brain regions of the patient after treatment with aducanumab showed low levels of amyloid that were preferentially found in the gyral crests, were associated with less tau pathology at autopsy, and were associated with slower longitudinal atrophy on in vivo magnetic resonance imaging (\u03b2\u2009=\u2009\u22120.50 [95% CI, \u22120.62 to \u22120.37];\n t<\/jats:italic>\n \u2009=\u2009\u22127.96 and\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). In contrast, the patient\u2019s brain regions with high amyloid burden were preferentially found in the sulcal depths and had similar levels of tau pathology as seen at autopsy in the untreated controls.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this case report, areas of extensive amyloid clearance after amyloid-targeting therapy were associated with less downstream neuropathologic change. In addition, amyloid clearance appears to preferentially occur in the gyral crests. Future studies should evaluate the differential mechanisms involved in amyloid clearance from superficial and deep cortical layers and in gyri and sulci because extensive amyloid clearance may be necessary to achieve downstream neuropathologic benefit after removal of amyloid.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.13058","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T17:30:17Z","timestamp":1783877417000},"page":"1247","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease"],"prefix":"10.1001","volume":"336","author":[{"given":"Christopher A.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhitsu R.","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"McGrew","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EunRan","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana M.","family":"Van Deerlin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya M.","family":"Nasrallah","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Mechanic-Hamilton","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Yushkevich","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wolk","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7618","key":"jpc260001r1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u00df plaques in Alzheimer\u2019s disease.","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"2","key":"jpc260001r2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease.","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"jpc260001r3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"jpc260001r4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"jpc260001r5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","article-title":"Alzheimer disease neuropathology in a patient previously treated with aducanumab.","volume":"144","author":"Plowey","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"5","key":"jpc260001r6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-023-02631-8","article-title":"Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.","volume":"146","author":"VandeVrede","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"5","key":"jpc260001r7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke.","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"jpc260001r8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","article-title":"Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study.","volume":"24","author":"Boon","year":"2025","journal-title":"Lancet Neurol"},{"key":"jpc260001r9","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1212\/WNL.96.15_supplement.2448","article-title":"EMBARK: a phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer's disease.","volume":"96","author":"Castrillo-Viguera","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"jpc260001r10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jalz.2013.06.003","article-title":"A platform for discovery: the University of Pennsylvania Integrated Neurodegenerative Disease Biobank.","volume":"10","author":"Toledo","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"1","key":"jpc260001r11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JAD-190283","article-title":"Longitudinal mapping of cortical thickness measurements: an Alzheimer\u2019s Disease Neuroimaging Initiative\u2013based evaluation study.","volume":"71","author":"Tustison","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"jpc260001r12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70346","article-title":"Tau burden is best captured by magnitude and extent: Tau-MaX as a measure of global tau.","volume":"21","author":"Brown","year":"2025","journal-title":"Alzheimers Dement"},{"key":"jpc260001r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data.","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"issue":"1","key":"jpc260001r14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14378","article-title":"Positron emission tomography harmonization in the Alzheimer\u2019s Disease Neuroimaging Initiative: a scalable and rigorous approach to multisite amyloid and tau quantification.","volume":"21","author":"Landau","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"6","key":"jpc260001r15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00401-022-02495-4","article-title":"TREM2 risk variants are associated with atypical Alzheimer\u2019s disease.","volume":"144","author":"Kim","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"2","key":"jpc260001r16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/jamaneurol.2025.4974","article-title":"Evaluation of copathology and clinical trajectories in individuals with tau-clinical mismatch.","volume":"83","author":"Brown","year":"2026","journal-title":"JAMA Neurol"},{"issue":"6760","key":"jpc260001r17","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads3204","article-title":"Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.","volume":"389","author":"Pizzo","year":"2025","journal-title":"Science"},{"issue":"8","key":"jpc260001r18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease.","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"jpc260001r19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2990.2007.00926.x","article-title":"Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology.","volume":"34","author":"Carare","year":"2008","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"jpc260001r20","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","article-title":"Associations between tau, A\u00df, and cortical thickness with cognition in Alzheimer disease.","volume":"92","author":"Ossenkoppele","year":"2019","journal-title":"Neurology"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2851619\/jama_brown_2026_pc_260001_1790887528.1674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:00:41Z","timestamp":1791903641000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2851619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":20,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.13058","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}